Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Negative Trials Matter: Anne Hege Aamodt Shares The TenCRAOS Trial
Anne Hege Aamodt/LinkedIn
Jan 31, 2026, 06:27

Negative Trials Matter: Anne Hege Aamodt Shares The TenCRAOS Trial

Anne Hege Aamodt, Member Board of Directors at European Stroke Organisation, shared on LinkedIn:

”Published today in The New England Journal of Medicine: the TenCRAOS trial.

We asked a difficult but important question: can early intravenous thrombolysis with tenecteplase improve vision after acute central retinal artery occlusion?

In this randomized phase 3 trial, the answer was no — and treatment was associated with serious safety concerns.

Negative trials matter.

TenCRAOS provides much-needed high-level evidence in a field where treatment decisions are often made under great uncertainty.

These results should inform clinical practice and future guidelines.

Deeply grateful to our multidisciplinary teams in neurology and ophthalmology for an inspiring collaboration, and to all investigators, supporters, and funders — and especially to the patients who generously participated.”

Read the full article here.

Article: A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion

Authors: Stephen J. Ryan; Øystein Kalsnes Jørstad; Mona Skjelland; Maiju Pesonen; Claus Z. Simonsen; Toke Bek; Rolf Ankerlund Blauenfeldt, Anne Hege Aamodt et al., for the TenCRAOS Investigators

Negative Trials Matter: Anne Hege Aamodt Shares The TenCRAOS Trial

Stay updated on all scientific advances with Hemostasis Today.

Acute Central Retinal Artery Occlusion Anne Hege Aamodt Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine NEJM TenCRAOS Tenecteplase thrombosis
NewsFeed